In clinical drug trials, it is appropriate to include as a covariate (a) any factor that is likely to differentially affect underlying rates of disease progression or (b) factors that are likely to differentially affect potential known mechanisms of action of the drug being studied or (c) both. With regard to therapeutic drug trials in Alzheimer disease (AD), a frequent and appropriate concern is whether the apolipoprotein E (ApoE) genotype should be taken as a covariate in statistical analyses regarding efficacy or adverse effects. The ApoE ε4 genotype is the major genetic risk factor identified for AD. The ApoE ε4 genotype is associated with earlier age of onset for the disease, with heterozygous patients having a 50% chance of dementia in their mid to late 70s and homozygous patients having a 50% chance of dementia in their mid to late 60s. The odds ratio for developing dementia also goes up significantly with gene dose. These associations hold true for both sporadic and familial forms of the illness. Pathologically, inheritance of the E4 genotype has been associated with greater total amyloid deposition in the brain, both in cortical plaques and in the vessels, and increased neurofibrillary tangles \[[@B1],[@B2]\]. In mild cognitive impairment (MCI) or very-early-stage AD, the E4 genotype is associated with greater deficits on the New York Paragraph Recall test, Auditory-Verbal Learning Test, and Buschke test at baseline. On magnetic resonance imaging, there are increases in both hippocampal atrophy and global atrophy at baseline \[[@B3]\], and on positron emission tomography using FDG (fluorine-18-fluorodeoxyglucose), there are greater deficits in glucose metabolism in the posterior parietal and parahippo-campal regions. In MCI subjects with the E4 genotype, cerebrospinal fluid analyses typically have shown decreased levels of the protein amyloid beta (Aβ) 1-42 and increased levels of Tau and pTau \[[@B4]\].

With regard to mechanisms of action with potential relevance to AD, the ApoE protein has been demonstrated to have several functions, which include its roles as a major cholesterol-carrying protein in plasma and as the primary lipid-carrying transport protein in the central nervous system \[[@B5]\]. The ApoE protein also functions as a major transporter for the Aβ proteins \[[@B6]\]. The ApoE2, E3, and E4 protein phenotypes have differential affinities for lipids and Aβ and consequent variable efficiencies in these transport roles. There is evidence in neuropathological studies of AD patients of greater microglial activation around Aβ plaques in patients with the ApoE 4 genotype \[[@B7]\]. These patients also demonstrate greater abnormal phosphorylation of Tau. In summary, the different ApoE2, E3, and E4 genotypes code for different ApoE protein phenotypes, which result in functional variation in the actions of this protein as it plays roles that virtually span known and theorized disease mechanisms involved in the pathogenesis or progression (or both) in AD.

With regard to the influence of the ApoE genotype on clinical factors of potential importance in AD clinical trials, there may be differential effects related to disease stage, trial length, and the specific effects of the drug regarding symptomatic actions versus effects on longer-term biological progression of the disease. In the original 12- to 26-week symptomatic trials of tacrine in mild to moderate AD, *post hoc*statistical analyses using the ApoE genotype to define subgroups of patients suggested that patients with the ApoE4 genotype progressed more rapidly on placebo and conversely were more likely to respond to treatment with tacrine \[[@B8]\]. However, later studies looking at the ApoE genotype as a factor in other cholinesterase inhibitor trials in mild to moderate AD (donepezil, rivastigmine, and galantamine) failed to confirm this hypothesized association \[[@B9]-[@B11]\].

Other short-term trials (6 weeks to 6 months) in mild- to moderate-stage AD with drugs believed to beneficially affect mitochondrial function, energy metabolism, and/or insulin resistance (caprylidene and rosiglitazone) were not positive overall, but subanalyses suggested that the subgroups with the ApoE2 or ApoE3 genotypes did significantly benefit \[[@B12]\]. However, with rosiglitazone, three later double-blind placebo-controlled studies of 1-year duration failed to reproduce or demonstrate bene-ficial effects in either the general AD population or the ApoE2 or ApoE3 genotype subgroups \[[@B13]\]. Overall, the influence of the ApoE genotype in shorter symptomatic studies in AD has been preliminary, negative, or equivocal.

Increased attention is being focused on an earlier stage of AD, MCI, in which several longer-duration trials have evaluated candidate drugs for delaying or preventing conversion from MCI to AD. The ApoE genotype does appear to play a more significant role in at least some of the longer MCI trials. In the Alzheimer Disease Cooperative Study group\'s MCI double-blind placebo-controlled trial (duration of 3 to 4 years) of donepezil or vitamin E versus placebo, MCI patients with the ApoE4 genotype on placebo were much more likely to progress and convert to AD \[[@B14]\]. Patients with the ApoE4 genotype showed significantly lower rates of conversion from MCI to AD versus placebo when treated with donepezil. Similar findings were seen in a large comparably designed double-blind placebo-controlled trial of rivastigmine in MCI. Thus, substantial evidence suggests that ApoE4-related differences in brain and disease progression may be observed in association with ApoE4 in MCI and that these effects may differentially influence detectable treatment effects.

The ApoE genotype also appears to have had differ-ential influence on adverse effects in a phase II AD treatment trial of a monoclonal antibody against Aβ (bapineuzumab). In this trial, subjects with the ApoE4 genotype were much more likely to develop vasogenic brain edema at lower doses of this antibody \[[@B15]\]. The known greater Aβ deposition in cerebral vasculature in AD patients with the ApoE4 genotype may or may not play a role in this phenomenon.

In summary, there is evidence that, through a variety of interactions and functional effects, variation in the ApoE genotype and the coded-for, different resultant polymorphic proteins may affect rates of disease progression in AD and potentially responses to therapies (with regard to both efficacy and safety). It therefore would seem prudent to stratify or include the ApoE genotype as a covariate in most AD therapeutic trials. Inclusion of the ApoE genotype should decrease variance in future studies, increasing the likelihood of successfully determining whether the drug under study benefits patients or is safe in treating AD.
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